AAAAAA

   
Results: 1-10 |
Results: 10
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS
Authors: Jacobson, JM Hafner, R Remington, J Farthing, C Holden-Wiltse, J Bosler, EM Harris, C Jayaweera, DT Roque, C Luft, BJ
Citation: Jm. Jacobson et al., Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS, AIDS, 15(5), 2001, pp. 583-589
Effect of IL-2 therapy on plasma hepatitis C virus-RNA levels in HIV/hepatitis C virus co-infected patients
Authors: Valdez, H Metcalf, JA Gripshover, BM Jacobson, JM Mitsuyasu, R Lederman, MM
Citation: H. Valdez et al., Effect of IL-2 therapy on plasma hepatitis C virus-RNA levels in HIV/hepatitis C virus co-infected patients, AIDS, 15(5), 2001, pp. 661-662
Pharmacokinetics, safety, and antiviral effects of hypericin, a derivativeof St. John's Wort plant, in patients with chronic hepatitis C virus infection
Authors: Jacobson, JM Feinman, L Liebes, L Ostrow, N Koslowski, V Tobia, A Cabana, BE Lee, DH Spritzler, J Prince, AM
Citation: Jm. Jacobson et al., Pharmacokinetics, safety, and antiviral effects of hypericin, a derivativeof St. John's Wort plant, in patients with chronic hepatitis C virus infection, ANTIM AG CH, 45(2), 2001, pp. 517-524
Thalidomide in low intermittent doses does not prevent recurrence of humanimmunodeficiency virus-associated aphthous ulcers
Authors: Jacobson, JM Greenspan, JS Spritzler, J Fox, L Fahey, JL Jackson, JB Chernoff, M Wohl, DA Pulvirenti, JJ Hooton, TM Shikuma, C
Citation: Jm. Jacobson et al., Thalidomide in low intermittent doses does not prevent recurrence of humanimmunodeficiency virus-associated aphthous ulcers, J INFEC DIS, 183(2), 2001, pp. 343-346
All-additive fabrication of inorganic logic elements by liquid embossing
Authors: Bulthaup, CA Wilhelm, EJ Hubert, BN Ridley, BA Jacobson, JM
Citation: Ca. Bulthaup et al., All-additive fabrication of inorganic logic elements by liquid embossing, APPL PHYS L, 79(10), 2001, pp. 1525-1527
Maximizing life's potentials in AIDS: A psychopharmacologic update
Authors: Cohen, MAA Jacobson, JM
Citation: Maa. Cohen et Jm. Jacobson, Maximizing life's potentials in AIDS: A psychopharmacologic update, GEN HOSP PS, 22(5), 2000, pp. 375-388
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
Authors: Jacobson, JM Lowy, I Fletcher, CV O'Neill, TJ Tran, DNH Ketas, TJ Trkola, A Klotman, ME Maddon, PJ Olson, WC Israel, RJ
Citation: Jm. Jacobson et al., Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults, J INFEC DIS, 182(1), 2000, pp. 326-329
All-inorganic field effect transistors fabricated by printing
Authors: Ridley, BA Nivi, B Jacobson, JM
Citation: Ba. Ridley et al., All-inorganic field effect transistors fabricated by printing, SCIENCE, 286(5440), 1999, pp. 746-749
Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection
Authors: Jacobson, JM Spritzler, J Fox, L Fahey, JL Jackson, JB Chernoff, M Wohl, DA Wu, AW Hooton, TM Sha, BE Shikuma, CM MacPhail, LA Simpson, DM Trapnell, CB Basgoz, N
Citation: Jm. Jacobson et al., Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection, J INFEC DIS, 180(1), 1999, pp. 61-67
Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection
Authors: Aziz, N Nishanian, P Taylor, JMG Mitsuyasu, RT Jacobson, JM Dezube, BJ Lederman, MM Detels, R Fahey, JL
Citation: N. Aziz et al., Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection, J INFEC DIS, 179(4), 1999, pp. 843-848
Risultati: 1-10 |